Related Experiment Video

Updated: May 14, 2026

Digital Polymerase Chain Reaction Assay for the Genetic Variation in a Sporadic Familial Adenomatous Polyposis Patient Using the Chip-in-a-tube Format
05:58

Digital Polymerase Chain Reaction Assay for the Genetic Variation in a Sporadic Familial Adenomatous Polyposis Patient Using the Chip-in-a-tube Format

Published on: August 20, 2018

Association between polymorphisms in PDCD1 gene and aplastic anemia in Chinese Han population

Zixia Wu1, Miao Miao, Yuhua Qiu

  • 1Department of Pharmacology, College of Pharmaceutical Science, Soochow University , Suzhou , People's Republic of China.

Leukemia & Lymphoma
|February 5, 2013
PubMed

Insights

Single nucleotide polymorphism (SNP) in the programmed cell death 1 (PD-1) gene may increase aplastic anemia risk. Specifically, the PD-1.1 G allele showed a correlation in a Chinese Han population study.

Area of Science:

  • Immunogenetics
  • Hematology
  • Molecular Biology

Background:

  • Single nucleotide polymorphisms (SNPs) in the programmed cell death 1 (PD-1) gene are linked to autoimmune diseases.
  • Aplastic anemia is a rare but serious condition affecting bone marrow function.

Purpose of the Study:

  • To investigate the association between PD-1 gene polymorphisms and aplastic anemia in a Chinese Han population.
  • To analyze the correlation of specific SNPs (PD-1.1 and PD-1.6) with aplastic anemia risk.

Main Methods:

  • Genotyping of two PD-1 SNPs (PD-1.1 G/A [rs36084323] and PD-1.6 G/A [rs10204525]) using direct sequencing.
  • Study included 166 aplastic anemia patients and 144 healthy controls from the Chinese Han population.
  • Analysis of genotype and allele distributions, ensuring Hardy-Weinberg equilibrium.

Main Results:

  • The G allele of the PD-1.1 SNP (rs36084323) was significantly associated with an increased risk of aplastic anemia.
  • No significant association was found between the PD-1.6 SNP (rs10204525) and aplastic anemia in this population.
  • Genotype distributions were in Hardy-Weinberg equilibrium for both patients and controls.

Conclusions:

  • The PD-1.1 G allele may be a risk factor for developing aplastic anemia in the Chinese Han population.
  • The PD-1.6 polymorphism does not appear to be associated with aplastic anemia risk in this cohort.
  • Further research is warranted to elucidate the role of PD-1 gene variations in aplastic anemia pathogenesis.

More Related Videos

High-resolution Melting PCR for Complement Receptor 1 Length Polymorphism Genotyping: An Innovative Tool for Alzheimer's Disease Gene Susceptibility Assessment07:26

High-resolution Melting PCR for Complement Receptor 1 Length Polymorphism Genotyping: An Innovative Tool for Alzheimer's Disease Gene Susceptibility Assessment

Published on: July 18, 2017

Related Concept Videos

Single Nucleotide Polymorphisms-SNPs01:05

Single Nucleotide Polymorphisms-SNPs

A single nucleotide polymorphism or SNP is a single nucleotide variation at a specific genomic position in a large population. It is the most prevalent type of sequence variation found in the human genome. Point mutations that occur in more than 1% of the population qualify as SNPs. These are present once every 1000 nucleotides on an average in the human genome. Replacement of a purine with another purine (A/G) or a pyrimidine with another pyrimidine (C/T) is known as a transition. In contrast,...
Genome-wide Association Studies-GWAS01:11

Genome-wide Association Studies-GWAS

Genome-wide association studies or GWAS are used to identify whether common SNPs are associated with certain diseases. Suppose specific SNPs are more frequently observed in individuals with a particular disease than those without the disease. In that case, those SNPs are said to be associated with the disease. Chi-square analysis is performed to check the probability of the allele likely to be associated with the disease.
GWAS does not require the identification of the target gene involved in...
Principles of Pharmacogenetics: Types of Genetic Variants01:27

Principles of Pharmacogenetics: Types of Genetic Variants

The human genome is over 99.9% identical between individuals, yet genetic differences exist at millions of bases. The human genome contains approximately 3 million variant positions per individual, many of which are heterozygous, contributing to genetic diversity and individual traits. Genetic variations include single-nucleotide polymorphisms (SNPs), insertions, deletions, and copy number variations (CNVs).SNPs, the most common variation, involve single-base changes in DNA. These can be...
Comparing Copy Number Variations and SNPs02:26

Comparing Copy Number Variations and SNPs

Sequencing of the human genome has opened up several best-kept secrets of the genome. Scientists have identified thousands of genome variations that exist within a population. These variations can be a single nucleotide or a larger chromosomal variation.
Copy number variations or CNVs are the structural variations that cover more than 1kb of DNA sequence. The single nucleotide polymorphism (SNP), on the other hand, is a single nucleotide change or a point mutation that is found in more than 1%...
Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase01:11

Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase

Genetic polymorphisms in drug targets have emerged as critical determinants of interindividual variability in drug response and toxicity. Pharmacogenomic investigations increasingly focus on identifying these variations to personalize and optimize therapeutic interventions. A drug target may be a receptor, enzyme, or signaling protein involved in pharmacologic responses or disease-related pathways. While early pharmacogenetic studies focused primarily on drug metabolism, current research...
Pharmacogenetic Phenotypes: Alterations in Pharmacokinetics, Drug Targets and Biologic Milieu01:29

Pharmacogenetic Phenotypes: Alterations in Pharmacokinetics, Drug Targets and Biologic Milieu

Genetic variations significantly influence drug response through pharmacokinetics, receptor interactions, and biologic milieu modifications. Pharmacokinetic alterations impact drug metabolism and clearance, affecting efficacy and toxicity. Variants in drug-metabolizing enzymes, such as CYP2C9 and CYP2C19, alter drug activation and elimination. For example, CYP2C9 loss-of-function variants require lower warfarin doses to prevent excessive bleeding, while CYP2C19 variants reduce clopidogrel...